Antibody-drug conjugates (ADCs) are a class of biopharmaceuticals that consist of a monoclonal antibody linked to a potent cytotoxic drug. The goal of ADC manufacturing is to produce a consistent, high-quality product that is safe and effective for use in treating various diseases, such as cancer. ADC manufacturing starts with the production of the antibody component. This can be done through a variety of methods, including recombinant DNA technology, hybridoma technology, or phage display. Once the antibody has been produced, it is conjugated to the drug using a chemical linker. This linker is designed to release the drug in a controlled manner when the ADC binds to its target, minimizing toxicity to normal cells. Next, the ADC is purified to remove any impurities and ensure the desired quality and consistency of the product. This is typically done using chromatography techniques such as protein A, ion exchange, or size exclusion. The purified ADC is then formulated and packaged for administration to patients. Overall, ADC manufacturing is a complex and multi-step process that requires careful attention .
